<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35567447</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2001-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Clinical and translational medicine</Title><ISOAbbreviation>Clin Transl Med</ISOAbbreviation></Journal><ArticleTitle>Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: Towards therapeutic targets and biomarkers.</ArticleTitle><Pagination><StartPage>e818</StartPage><MedlinePgn>e818</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e818</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/ctm2.818</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two devastating human neurodegenerative diseases. A hallmark pathological feature of both diseases is the depletion of the RNA-binding protein TDP-43 from the nucleus in the brain and spinal cord of patients. A major function of TDP-43 is to repress the inclusion of cryptic exons during RNA splicing. When it becomes depleted from the nucleus in disease, this function is lost, and recently, several key cryptic splicing targets of TDP-43 have emerged, including STMN2, UNC13A, and others. UNC13A is a major ALS/FTD risk gene, and the genetic variations that increase the risk for disease seem to do so by making the gene more susceptible to cryptic exon inclusion when TDP-43 function is impaired. Here, we discuss the prospects and challenges of harnessing these cryptic splicing events as novel therapeutic targets and biomarkers. Deciphering this new cryptic code may be a touchstone for ALS and FTD diagnosis and treatment.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Clinical and Translational Medicine published by John Wiley &amp; Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koike</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS123743</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097263</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG047126</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Transl Med</MedlineTA><NlmUniqueID>101597971</NlmUniqueID><ISSNLinking>2001-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="Y">Pick Disease of the Brain</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">UNC13A</Keyword></KeywordList><CoiStatement>Aaron D. Gitler is a scientific founder of Maze Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>14</Day><Hour>8</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35567447</ArticleId><ArticleId IdType="pmc">PMC9098226</ArticleId><ArticleId IdType="doi">10.1002/ctm2.818</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2010;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2010;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et&#xa0;al. Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2010;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier&#x2010;Tourenne C, Polymenidou M, Cleveland DW. TDP&#x2010;43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet. 2010;19:R46&#x2010;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Bell W, LaClair KD, et&#xa0;al. Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP&#x2010;43 inclusion but exhibiting nuclear clearance of TDP&#x2010;43. Acta Neuropathol. 2017;133:923&#x2010;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444385</ArticleId><ArticleId IdType="pubmed">28332094</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, et&#xa0;al. TDP&#x2010;43 repression of nonconserved cryptic exons is compromised in ALS&#x2010;FTD. Science. 2015;349:650&#x2010;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez&#x2010;Erauskin J, Baughn MW, et&#xa0;al. Premature polyadenylation&#x2010;mediated loss of stathmin&#x2010;2 is a hallmark of TDP&#x2010;43&#x2010;dependent neurodegeneration. Nat Neurosci. 2019;22:180&#x2010;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, et&#xa0;al. ALS&#x2010;implicated protein TDP&#x2010;43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167&#x2010;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Humphrey J, Pickles S, et&#xa0;al. Truncated stathmin&#x2010;2 is a marker of TDP&#x2010;43 pathology in frontotemporal dementia. J Clin Invest. 2020;130:6080&#x2010;6092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, et&#xa0;al. TDP&#x2010;43 represses cryptic exon inclusion in the FTD&#x2010;ALS gene UNC13A. Nature. 2022;603:124&#x2010;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, et&#xa0;al. TDP&#x2010;43 loss and ALS&#x2010;risk SNPs drive mis&#x2010;splicing and depletion of UNC13A. Nature. 2022;603:131&#x2010;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipstein N. Mechanism underlying a risk gene in neurodegeneration. Nature. 2022;603:33&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">35197585</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Russ J, Cali CP, et&#xa0;al. Loss of nuclear TDP&#x2010;43 is associated with decondensation of LINE retrotransposons. Cell Rep. 2019;27:1409&#x2010;1421.e1406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508629</ArticleId><ArticleId IdType="pubmed">31042469</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YI, Knowles DA, Humphrey J, et&#xa0;al. Annotation&#x2010;free quantification of RNA splicing using LeafCutter. Nat Genet. 2018;50:151&#x2010;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742080</ArticleId><ArticleId IdType="pubmed">29229983</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaquero&#x2010;Garcia J, Barrera A, Gazzara MR, et&#xa0;al. A new view of transcriptome complexity and regulation through the lens of local splicing variations. Elife. 2016;5:e11752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4801060</ArticleId><ArticleId IdType="pubmed">26829591</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, Van Deerlin VM, van Swieten JC, et&#xa0;al. C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome&#x2010;wide meta&#x2010;analysis. Ann Neurol. 2014;76:120&#x2010;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4137231</ArticleId><ArticleId IdType="pubmed">24931836</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CG, et&#xa0;al. Genome&#x2010;wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083&#x2010;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, et&#xa0;al. Genome&#x2010;wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97:1268&#x2010;1283.e1266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Placek K, Baer GM, Elman L, et&#xa0;al. UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2019;73:190&#x2010;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251755</ArticleId><ArticleId IdType="pubmed">30368160</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Mullen B, Wojtas A, et&#xa0;al. Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol Neurodegener. 2014;9:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4190282</ArticleId><ArticleId IdType="pubmed">25239657</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Ren Y. Genome&#x2010;wide analyses as part of the international FTLD&#x2010;TDP whole&#x2010;genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathol. 2019;137:879&#x2010;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6533145</ArticleId><ArticleId IdType="pubmed">30739198</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S. The genetics of Caenorhabditis elegans . Genetics. 1974;77:71&#x2010;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin I, Rosenmund C, S&#xfc;dhof TC, et&#xa0;al. Munc13&#x2010;1 is essential for fusion competence of glutamatergic synaptic vesicles. Nature. 1999;400:457&#x2010;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">10440375</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, et&#xa0;al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron&#x2010;specific biology. Nat Genet. 2021;53:1636&#x2010;1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, van Vught PW, van Rheenen W, et&#xa0;al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33:630.e633&#x2010;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal&#x2010;Taboada JM, Lopez&#x2010;Lopez A, Salvado M, et&#xa0;al. UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort. J Neurol. 2015;262:2285&#x2010;2292.</Citation><ArticleIdList><ArticleId IdType="pubmed">26162714</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Jiang H, Wang F, et&#xa0;al. UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta&#x2010;analysis. Neurol Sci. 2019;40:2293&#x2010;2302.</Citation><ArticleIdList><ArticleId IdType="pubmed">31201598</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HHG, Westeneng HJ, van der Burgh HK, et&#xa0;al. The distinct traits of the UNC13A polymorphism in amyotrophic lateral sclerosis. Ann Neurol. 2020;88:796&#x2010;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7540607</ArticleId><ArticleId IdType="pubmed">32627229</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43&#x2010;mediated neurodegeneration. Nat Rev Neurosci. 2011;13:38&#x2010;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipstein N, Verhoeven&#x2010;Duif NM, Michelassi FE, et&#xa0;al. Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder. J Clin Invest. 2017;127:1005&#x2010;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5330740</ArticleId><ArticleId IdType="pubmed">28192369</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra San Juan I, Nash LA, Smith KS, et&#xa0;al. Loss of mouse Stmn2 function causes motor neuropathy. Neuron. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9119928</ArticleId><ArticleId IdType="pubmed">35294901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11:125&#x2010;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4743652</ArticleId><ArticleId IdType="pubmed">22262036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D. Promise of nucleic acid therapeutics for amyotrophic lateral sclerosis. Ann Neurol. 2022;91:13&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">34704267</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, et&#xa0;al. Nusinersen versus sham control in infantile&#x2010;onset spinal muscular atrophy. N Engl J Med. 2017;377:1723&#x2010;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Sivakumar P, Humphrey J, et&#xa0;al. Mice with endogenous TDP&#x2010;43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 2018;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983119</ArticleId><ArticleId IdType="pubmed">29764981</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Zhang F, Gao G. CRISPR&#x2010;based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell. 2020;181:136&#x2010;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236621</ArticleId><ArticleId IdType="pubmed">32243786</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Zhou S, Cai H, et&#xa0;al. VEGF levels in CSF and serum in mild ALS patients. J Neurol Sci. 2014;346:216&#x2010;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">25204587</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Otto M, Silani V. Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2021;15:679199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8255624</ArticleId><ArticleId IdType="pubmed">34234641</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Karnaros V, Benyamin B, et&#xa0;al. Urinary neopterin: a novel biomarker of disease progression in amyotrophic lateral sclerosis. Eur J Neurol. 2022;29:990&#x2010;999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901536</ArticleId><ArticleId IdType="pubmed">34967083</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Silani V, Otto M. Neurochemical biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. 2019;32:747&#x2010;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">31403480</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Hardiman O, Al&#x2010;Chalabi A, et&#xa0;al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35334233</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus&#x2010;Hernandez M, Mackenzie IR, Boeve BF, et&#xa0;al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;linked FTD and ALS. Neuron. 2011;72:245&#x2010;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et&#xa0;al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron. 2011;72:257&#x2010;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, et&#xa0;al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2010;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, et&#xa0;al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide&#x2010;repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2010;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Ba&#xf1;ez&#x2010;Coronel M, et&#xa0;al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci USA. 2013;110:E4968&#x2010;4977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, et&#xa0;al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72&#x2010;associated amyotrophic lateral sclerosis. Sci Transl Med. 2017;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z, Zhang Y, Gendron TF, et&#xa0;al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)&#x2010;associated defects in c9FTD/ALS. Neuron. 2014;83:1043&#x2010;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, et&#xa0;al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2010;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier&#x2010;Tourenne C, Baughn M, Rigo F, et&#xa0;al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA. 2013;110:E4530&#x2010;4539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, Montrasio F, Pattamatta A, et&#xa0;al. Antibody therapy targeting RAN proteins rescues C9 ALS/FTD phenotypes in C9orf72 mouse model. Neuron. 2020;105:645&#x2010;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391607</ArticleId><ArticleId IdType="pubmed">31831332</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Guo S, Bardhi O, et&#xa0;al. Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice. Proc Natl Acad Sci USA. 2020;117:18591&#x2010;18599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7414156</ArticleId><ArticleId IdType="pubmed">32690681</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh W, Pan W, Gawad C, et&#xa0;al. Noninvasive in vivo monitoring of tissue&#x2010;specific global gene expression in humans. Proc Natl Acad Sci USA. 2014;111:7361&#x2010;7366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4034220</ArticleId><ArticleId IdType="pubmed">24799715</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E, Pera MC, Scoto M, et&#xa0;al. Spinal muscular atrophy &#x2010; insights and challenges in the treatment era. Nat Rev Neurol. 2020;16:706&#x2010;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">33057172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, et&#xa0;al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17:104&#x2010;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado DA, Davidson BL. Gene therapy for ALS: a review. Mol Ther. 2021;29:3345&#x2010;3358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni J, Ren Y, Su T, et&#xa0;al. Loss of TDP&#x2010;43 function underlies hippocampal and cortical synaptic deficits in TDP&#x2010;43 proteinopathies. Mol Psychiatry. 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34697451</ArticleId></ArticleIdList></Reference><Reference><Citation>Armakola M, Higgins MJ, Figley MD, et&#xa0;al. Inhibition of RNA lariat debranching enzyme suppresses TDP&#x2010;43 toxicity in ALS disease models. Nat Genet. 2012;44:1302&#x2010;1309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510335</ArticleId><ArticleId IdType="pubmed">23104007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, et&#xa0;al. RNA binding antagonizes neurotoxic phase transitions of TDP&#x2010;43. Neuron. 2019;102:321&#x2010;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Donde A, Sun M, Ling JP, et&#xa0;al. Splicing repression is a major function of TDP&#x2010;43 in motor neurons. Acta Neuropathol. 2019;138:813&#x2010;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802294</ArticleId><ArticleId IdType="pubmed">31332509</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>